معرفی
Bruce Haffty is a Professor in the Department of Therapeutic Radiology at Yale School of Medicine. He received his MD from Yale University in 1984 and became board certified in Radiation Oncology by the American Board of Radiology in 1988. With over 35 years of experience in the field, Dr. Haffty has established himself as a leading expert in radiation oncology, particularly in the treatment of breast cancer.
Dr. Haffty's research program spans multiple critical areas in radiation oncology including radiogenomics, proton therapy applications, and treatment timing optimization. His recent publications demonstrate a strong focus on improving clinical outcomes through evidence-based approaches to radiation therapy for breast cancer patients. He has conducted significant research on predicting radiation-induced toxicity, examining genetic factors affecting treatment response, and addressing systemic barriers to cancer treatment completion.
His research methodology combines clinical trials, retrospective analyses, and large-scale collaborative studies with national and international partners. Dr. Haffty frequently collaborates with Meena S. Moran, MD, and participates in major cooperative groups including the Alliance for Clinical Trials in Oncology and PTCOG (Particle Therapy Co-Operative Group).
- Key Research Areas:
- Radiation therapy optimization for breast cancer
- Radiogenomics and personalized radiation therapy
- Proton therapy applications in breast cancer
- Barriers to cancer treatment completion
- Genetic factors influencing radiation response
- Hypofractionated radiation protocols
Dr. Haffty's work bridges basic science discoveries with clinical applications, aiming to translate molecular insights into improved patient outcomes. His recent publications in high-impact journals demonstrate ongoing productivity and relevance to current clinical practice in radiation oncology.
His research has practical implications for radiation dosing, treatment timing, and personalized approaches to radiation therapy, directly impacting clinical decision-making for breast cancer patients. Dr. Haffty maintains an active research program with publications spanning from basic molecular mechanisms to large-scale clinical implementation studies.